CEO Today - UK Awards 2022

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS. At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV treatment and care. If you should know one thing about us, know this: we will not rest until we leave no person living with HIV behind. Until the 38 million people living with HIV is down to zero, we will continue searching for new ways to limit the impact of HIV.1 Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our employees located across the globe, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV isn’t. Our current portfolio of HIV treatments is our first step in fighting back against the disease. This is only the beginning, as our research center in Branford, Connecticut, the world’s only HIV-dedicated facility, which is uniquely focused on finding new innovative medicines to help improve the lives of people living with HIV. Also searching to find major breakthroughs against HIV is our industry-defining partnership with the HIV Cure Center at the University of North Carolina. Part of a unique public-private collaboration with Qura Therapeutics, we have been combining resources and expertise to accelerate novel breakthroughs and maximize the chance of finding an HIV cure. Alongside our novel approach to R&D, improving access to medicines is just as important in delivering results for people living with HIV. At ViiV Healthcare, we are dedicated to widening access to ensure those who need our medicines can receive them. Collaborations with organizations such as IAS, CHAI and MPP enable our medicines to make the greatest possible impact in countries around the world. As an example, our voluntary license agreements allow generic manufacturers to develop pediatric formulations of our medicines where 99% of children living with HIV live. We are committed to working ever closer with our partners through continued access initiatives. To accelerate the HIV response, we put significant focus on community initiatives to strengthen local healthcare services for people living with HIV. Through our Positive Action programs, which back more than 300 projects worldwide, our work with local communities aim to deliver long-lasting impacts on groups such as women and children. We seek to enhance local expertise and resources that build toward global goals, as well as our own dedicated mission of leaving no person living with HIV behind. Our History & Mission Since our founding, we have worked to take a deeper and broader interest in HIV and AIDS than any company has done before. We’re committed to new approaches that deliver effective and innovative medicines for HIV treatment and prevention. www. ceotodaymagazine . com CEO Today Un i t ed Ki ngdom Awa rds 202 2 Hea l t hca re Leade r of t he Yea r CEO, Vi iV Healthcare Deborah Waterhouse Te l : + 1 8 7 7 V i i V U S A ( + 1 8 7 7 8 4 4 8 8 7 2 ) | w w w . v i i v h e a l t h c a r e . c o m 19 We will not rest until we leave no person living with HIV behind.

RkJQdWJsaXNoZXIy Mjk3Mzkz